2025
Real-World Rollout of Injectable Antiretrovirals for HIV Prevention and Treatment: Correlates of Early Adoption
Koshy L, Payne E, Barakat L, Hao R, Sureshanand S, Ornelas A, Dewan A, Meyer J. Real-World Rollout of Injectable Antiretrovirals for HIV Prevention and Treatment: Correlates of Early Adoption. Open Forum Infectious Diseases 2025, ofaf029. DOI: 10.1093/ofid/ofaf029.Peer-Reviewed Original ResearchLAI-PrEPLAI-ARTSocial determinants of healthSubstance use disordersDeterminants of healthLong-actingRetrospective cohortRetrospective cohort of patientsSocial determinantsHIV preventionCohort of patientsFisher's exact testPre-exposure prophylaxisOvercome health inequitiesHealth equity lensPrEP patientsChi-square testUrban health systemMedian ageBivariate logistic regressionOral PrEPPublic health interventionsBackground DataExact testHIV treatment
2022
Overlapping needs for sexual and reproductive health and HIV prevention in women with substance use disorders
Gibson B, Hoff E, Haas A, Adams ZM, Price CR, Goddard-Eckrich D, Sheth SS, Dasgupta A, Meyer JP. Overlapping needs for sexual and reproductive health and HIV prevention in women with substance use disorders. Women's Health 2022, 18: 17455065211070543. PMID: 35023410, PMCID: PMC8771433, DOI: 10.1177/17455065211070543.Peer-Reviewed Original ResearchConceptsSubstance use disordersPre-exposure prophylaxisUse disordersHIV preventionReproductive healthReproductive health service utilizationHigh HIV risk behaviorHealth service utilizationUnique health issuesCross-sectional evaluationHIV risk behaviorsHigh unmet needReproductive health behaviorsReproductive health needsConcurrent clinical trialsForm of contraceptionTime of assessmentPregnancy intentionReproductive ageClinical trialsUnintended pregnancyService utilizationCriminal justice involvementDrug treatmentContraceptive use
2021
Preference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders
Meyer J, Price C, Tracey D, Sharpless L, Song Y, Madden L, Elwyn G, Altice F. Preference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders. Patient Preference And Adherence 2021, 15: 1913-1927. PMID: 34511887, PMCID: PMC8420782, DOI: 10.2147/ppa.s315543.Peer-Reviewed Original ResearchSubstance use disordersPersonal HIV riskHIV preventionAddiction treatment servicesHIV riskUse disordersTreatment servicesPatient-centered decision aidAwareness of PrEPHIV prevention cascadeInitiation of PrEPPre-exposure prophylaxisOpioid use disorderStandard of careDecision aidAlcohol use severityHalf of participantsAddiction treatment programsDA participantsPrevention cascadePrimary outcomeIndependent correlatesHigh riskDecisional preferencesHigher alcohol use severityChapter 11 HIV pre-exposure prophylaxis for people who inject drugs
Shrestha R, McCoy-Redd B, Meyer J. Chapter 11 HIV pre-exposure prophylaxis for people who inject drugs. 2021, 223-236. DOI: 10.1016/b978-0-323-68328-9.00011-4.Peer-Reviewed Original ResearchHIV preventionEffective HIV prevention toolHigh-risk sexual networksHIV pre-exposure prophylaxisLimited clinical trial dataSubstance usePre-exposure prophylaxisHIV prevention toolClinical trial dataHarm reduction programsKey target populationSubstance use disordersPart of patientsTarget populationPrEP outcomesPreexposure prophylaxisMedication adherenceHIV riskUse disordersTrial dataPWIDSexual networksPrEPPrevention toolProphylaxis